Pharma
Novo Nordisk cuts 9,000 jobs – stock increases
Saving at All Costs: The restructuring will cost eight billion Danish kroner – from 2026 onwards, the savings are expected to flow back annually to the same extent.
Novo Nordisk announces the largest job cuts in its history: 9,000 jobs will be eliminated, more than half of them in Denmark. This corresponds to 11.5 percent of the workforce. The restructuring will initially cost around 1.07 billion euros but is expected to save the same amount annually from 2026.
Three Harsh Truths from the Inflation Shock
Simultaneously, the pharmaceutical company lowers its forecast: For 2025, Novo now expects an operating profit increase of only 4 to 10 percent instead of the previous 10 to 16 percent. Investors react calmly – the stock temporarily rose by 1.2 percent to 342.75 Danish kroner.
The focus is on the multi-billion market for diabetes and obesity medications like Wegovy and Ozempic. Novo aims to free up resources through restructuring to expand its leading position here.
